Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 213


Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients.

Jung MY, Hwang SY, Hong YA, Oh SY, Seo JH, Lee YM, Park SW, Kim JS, Wang JK, Kim JY, Lee JE, Ko GJ, Pyo HJ, Kwon YJ.

Kidney Res Clin Pract. 2015 Mar;34(1):20-7. doi: 10.1016/j.krcp.2014.11.003. Epub 2015 Jan 15.


Correlation between CRP and early failure of arteriovenous fistula (AVF).

Khavanin Zadeh M, Mohammadipour S, Omrani Z.

Med J Islam Repub Iran. 2015 Jun 8;29:219. eCollection 2015.


The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.

Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators.

PLoS One. 2015 Oct 9;10(10):e0140241. doi: 10.1371/journal.pone.0140241. eCollection 2015.


Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease.

Shukla AM, Bose C, Karaduta OK, Apostolov EO, Kaushal GP, Fahmi T, Segal MS, Shah SV.

PLoS One. 2015 Sep 28;10(9):e0139226. doi: 10.1371/journal.pone.0139226. eCollection 2015.


Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis.

Agüera ML, Martin-Malo A, Alvarez-Lara MA, Garcia-Montemayor VE, Canton P, Soriano S, Aljama P.

PLoS One. 2015 Aug 31;10(8):e0135967. doi: 10.1371/journal.pone.0135967. eCollection 2015.


Successful creation of an anemia management algorithm for hemodialysis patients.

Hara K, Mizutani Y, Kodera H, Miyake M, Yasuda Y, Ohara S.

Int J Nephrol Renovasc Dis. 2015 Jun 23;8:65-75. doi: 10.2147/IJNRD.S80723. eCollection 2015.


Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study.

Kuo TH, Tseng CT, Lin WH, Chao JY, Wang WM, Li CY, Wang MC.

Medicine (Baltimore). 2015 Jul;94(26):e1032. doi: 10.1097/MD.0000000000001032.


From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter?

Toto RD.

Circulation. 2015 Jul 7;132(1):7-9. doi: 10.1161/CIRCULATIONAHA.115.017177. Epub 2015 Jun 9. No abstract available.


Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Koury MJ, Haase VH.

Nat Rev Nephrol. 2015 Jul;11(7):394-410. doi: 10.1038/nrneph.2015.82. Epub 2015 Jun 9. Review.


The Labile Side of Iron Supplementation in CKD.

Slotki I, Cabantchik ZI.

J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681/ASN.2015010052. Epub 2015 May 21.


Left ventricular dysfunction in the haemodialysis population.

Sood MM, Pauly RP, Rigatto C, Komenda P.

NDT Plus. 2008 Aug;1(4):199-205. doi: 10.1093/ndtplus/sfn074.


Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Ghareeb M, Akhlaghi F.

Bioanalysis. 2015;7(8):1037-58. doi: 10.4155/bio.15.35.


Role of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study.

MacRae JM, Ahmed S, Hemmelgarn B, Sun Y, Martin BJ, Roifman I, Anderson T.

Can J Kidney Health Dis. 2015 May 4;2:19. doi: 10.1186/s40697-015-0055-8. eCollection 2015.


Individualizing anaemia therapy.

de Francisco AL.

NDT Plus. 2010 Dec;3(6):519-26. doi: 10.1093/ndtplus/sfq164. Epub 2010 Sep 21.


American Society of Nephrology Quiz and Questionnaire 2014: RRT.

Mehrotra R, Perazella MA, Choi MJ.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1100-6. doi: 10.2215/CJN.01490215. Epub 2015 Apr 20.


Red cell physiology and signaling relevant to the critical care setting.

Said A, Rogers S, Doctor A.

Curr Opin Pediatr. 2015 Jun;27(3):267-76. doi: 10.1097/MOP.0000000000000225.


Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes.

Thamer M, Zhang Y, Kaufman J, Cotter D, Hernán MA.

J Endocrinol Diabetes. 2014;1(2). doi: 10.15226/2374-6890/1/2/00111.


A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada.

Tsao NW, Lo C, Leung M, Marin JG, Martinusen D.

Can J Kidney Health Dis. 2014 Nov 11;1:28. doi: 10.1186/s40697-014-0028-3. eCollection 2014.


Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.

Qunibi WY.

J Am Soc Nephrol. 2015 Oct;26(10):2311-3. doi: 10.1681/ASN.2015020135. Epub 2015 Mar 3. No abstract available.


Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP; Collaborative Study Group.

J Am Soc Nephrol. 2015 Oct;26(10):2578-87. doi: 10.1681/ASN.2014080842. Epub 2015 Mar 3.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk